Derek Chalmers, Cara Therapeutics CEO

Cara lines up a $440M deal for US rights to its late-stage drug for se­vere itch, with $150M cash on the ta­ble

With plans afoot to file an NDA for what could be its first ap­proved drug, Cara Ther­a­peu­tics is piv­ot­ing its fo­cus to com­mer­cial­iza­tion. And Swiss com­pa­ny Vi­for Phar­ma is will­ing to sur­ren­der up to $440 mil­lion to mar­ket the can­di­date in the US.

Cara $CARA CEO Derek Chalmers said an NDA sub­mis­sion is com­ing this quar­ter for their in­tra­venous drug Ko­r­su­va in chron­ic kid­ney dis­ease-as­so­ci­at­ed pru­ri­tus (CKD-aP), a se­vere itch­ing con­di­tion. The Stam­ford, CT-based biotech read out pos­i­tive topline da­ta from a Phase III piv­otal study back in April, and an­nounced plans to ap­proach EMA reg­u­la­tors short­ly af­ter fil­ing with the FDA.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.